![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Molecular and Cellular Biology, October 2002, p. 7279-7290, Vol. 22, No. 20
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.20.7279-7290.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Cell Biology and Signal Transduction Research Group, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
Received 4 June 2002/ Returned for modification 2 July 2002/ Accepted 22 July 2002
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1 (PLC-1), the p85
subunit of phosphatidylinositol 3-kinase (PI3K), GAP, and Cbl (32, 33, 44). Formation of the receptor-signaling protein complexes then initiates the activation of various signaling pathways. For example, the interaction between EGFR and SHC/Grb2 results in the recruitment of Sos to the plasma membrane to activate Ras. Activated Ras mediates Raf activation, which then phosphorylates and activates mitogen-activated protein kinase kinase and extracellular-signal-regulated kinase (ERK), leading to the activation of transcriptional factors c-Fos and c-Jun (27, 28, 32). This "Ras pathway" has been elucidated and is necessary for EGF-stimulated DNA synthesis. In addition, activation of PI3K by EGFR stimulates Akt/protein kinase B activity, which protects against apoptosis (3, 15). Concomitant with the activation of various signaling pathways by EGF, the binding of EGF also rapidly triggers the clustering and internalization of ligand-receptor complexes via coated pits and coated vesicles (5, 34). The fate of internalized EGF and EGFR is primarily proteolytic degradation in lysosomes (5). However, whether endocytosis leads exclusively to receptor inactivation or is important in maintaining, triggering, or amplifying cellular responses to growth factors remains an important question (7, 12, 13). It is well established that endocytosis of EGFR from the cell surface to lysosomes results in degradation of the receptor, which can attenuate receptor signaling and may even be conceived of as a tumor suppressor pathway (10, 13). On the other hand, accumulated evidence suggests that the internalized EGF-EGFR complex may maintain its ability to generate cell signaling from endosomes. Internalized EGFR is autophosphorylated and catalytically active (11, 21, 23). Various signaling molecules that regulate Ras activity, including Grb2, SHC, GAP, and Cbl, are cointernalized with EGFR into endosomes and remain associated with the receptor in endosomes (10, 14, 17, 25, 40). Recently, more results confirmed the interaction between EGFR and various signaling proteins in endosomes (4, 19, 22, 31, 37).
More evidence supporting endosomal signaling comes from endocytosis-blocking experiments. Inhibition of EGFR endocytosis by a dominant-negative mutant dynamin enhances cell proliferation but decreases ERK activation (39). In a recent study of EGFR transactivation by G protein-coupled receptors, it was found that inhibition of EGFR endocytosis by either mutant dynamin or ß-arrestin abolished ERK activation (1, 29). Inhibition of EGFR endocytosis by phospholipase D also blocks EGF-stimulated ERK activation (36). However, in the few cases where biological end points were measured, inhibition of endocytosis did not result in attenuation of biological effects (6, 39). Very recently, it was reported that retrograde support of neuronal survival does not require the retrograde transport (endocytosis) of nerve growth factor (26). These results argue against the physiological relevance of endosome-originated signals (12). So far, the controversy over endosomal signaling and its physiological relevance remains unsolved. The lack of breakthrough is due to the limitation of current approaches. For example, while it has made a significant contribution and remains a powerful tool to study endosomal signaling, the endocytosis inhibition approach has its limitations. While inhibition of EGFR endocytosis eliminates endosomal signaling, the retention of EGFR at the cell surface also enhances signaling from the plasma membrane. Thus, it is difficult to determine whether the observed effects are due to the lack of endosomal signaling or due to prolonged plasma membrane signaling. Blocking EGFR endocytosis by mutant dynamin or ß-arrestin affects all endocytic events mediated by these factors. Thus, it is difficult to determine whether the observed effects are due to the inhibition of EGFR endosomal signaling or due to a broad inhibition of endocytosis. Moreover, this approach is not suitable for studying the dynamics of endosomal signaling. Up to now, none of the current approaches offered a means to get activated receptors inside a cell without initial activation at the cell surface (43).
Here we report the establishment of a system that allows the specific activation of endosome-associated EGFR without the activation of the plasma membrane-associated EGFR and without disrupting the overall endocytosis pathway. By using this novel system, we provided original evidence demonstrating that (i) the endosome can serve as a nucleation site for the formation of signaling complexes, (ii) endosomal EGFR signaling is sufficient to activate the major signaling pathways leading to cell proliferation and survival, and (iii) endosomal EGFR signaling is sufficient to suppress apoptosis induced by serum withdrawal.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1 antibody was from Medicore (Montreal, Quebec, Canada). Mouse anti-Rab5 and anti-early endosome autoantigen 1 (EEA1) antibodies were from BD Signal Transduction. Glutathione cross-linked to 4% agarose and goat anti-mouse immunoglobulin G (IgG) conjugated with agarose were from Sigma (St. Louis, Mo.). Protein A-Sepharose 6MB was from Pharmacia BioProcess (Uppsala, Sweden). AG-1478 and monensin were from Calbiochem (La Jolla, Calif.). EGF was from Upstate Biotechnology. Unless otherwise specified, all the chemicals were purchased from Sigma. Cell culture and treatment. MDCK and BT20 cells were grown at 37°C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) and were maintained in a 5% CO2 atmosphere. To specifically activate EGFR after its endocytosis into endosomes, MDCK and BT20 cells were serum starved for 24 h. After the cells were pretreated with 0.5 µM AG-1478 for 15 min, monensin and EGF/Texas red-conjugated EGF (TR-EGF) were added to final concentrations of 100 µM and 100 ng/ml, respectively. After a 30-min treatment, the cells were washed with phosphate-buffered saline (PBS) three times and then maintained in the serum-free medium for various times indicated in figures. Alternatively, MDCK and BT20 cells were pretreated with 0.5 µM AG-1478 for 15 min, and then EGF/TR-EGF was added to a final concentration of 100 ng/ml. After a 30-min treatment, the cells were cooled down to 4°C and washed with acidic stripping buffer (100 mM acetic acid, 150 mM NaCl [pH 2.7]) (42) for 1 min. The cells were then washed with PBS three times and incubated in serum-free medium for various times.
Subcellular fractionation and total-cell lysates. Isolation of plasma membrane (PM), endosomal (EN), and cytosolic (CY) fractions was carried out by our previously described method (41). Briefly, following treatment cells were scraped into homogenization buffer (0.25 M sucrose, 20 mM Tris-HCl [pH 7], 1 mM MgCl2, 4 mM NaF, 0.5 mM Na3VO4, 0.02% NaN3, 0.1 mM 4-[2-aminoethyl]-benzenesulfonyl fluoride, 10 µg of aprotinin/ml, 1 µM pepstatin A) and homogenized. The homogenates were centrifuged at 200 x g for 5 min to remove cell debris and nuclei (p1). The postnuclear supernatant (S1) was then centrifuged at 1,500 x g for 10 min to yield a supernatant (S2) and a pellet (P2). Next, P2 was resuspended in homogenization buffer (0.25 M sucrose), overlaid upon an equal volume of 1.42 M sucrose buffer, and centrifuged at 82,000 x g for 1 h. The pellicule at the 0.25-to-1.42 M interface was collected as the PM fraction. The S2 fraction was centrifuged at 100,000 x g for 30 min to yield the soluble CY fraction and a microsomal pellet. This pellet was resuspended in 0.25 M sucrose buffer and overlaid on a discontinuous sucrose gradient containing equal volumes of homogenization buffer at 1.00 and 1.15 M sucrose. The resuspension was centrifuged at 200,000 x g for 1.5 h to obtain the purified EN fraction at the 0.25-to-1.00 M interface. For a typical experiment, the total yield is 30 µg for the plasma membrane, 30 µg for the EN fraction, and 1 mg for the CY fraction. The total yields of each fraction were very consistent for all of the treatments.
Indirect immunofluorescence. Indirect immunofluorescence was performed as described previously (41). Briefly, cells were grown on glass coverslips and serum starved for 24 h. After treatment, the cells were fixed by methanol and permeabilized with 0.2% Triton X-100. Next, the cells were incubated with primary antibodies at room temperature for 1 h followed by fluorescence-labeled secondary antibodies for 1 h.
Immunoprecipitation and immunoblotting. Immunoprecipitation experiments were carried out as described previously (41). Cells were lysed with immunoprecipitation buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 100 mM NaF, 0.5 mM Na3VO4, 0.02% NaN3, 0.1 mM 4-[2-aminoethyl]-benzenesulfonyl fluoride, 10 µg of aprotinin/ml, 1 µM pepstatin A) overnight at 4°C. Cell lysates were then centrifuged at 21,000 x g for 30 min to remove debris. The supernatants, containing 1 mg of total protein, were incubated with 1 µg of mouse anti-EGFR antibody to immunoprecipitate EGFR from BT20 and MDCK cells. For control experiments, primary antibodies were replaced with normal mouse or sheep IgG (Sigma), and no EGFR was precipitated by normal IgG.
Ras activation assay. Ras activation was assayed by the method described by Herrmann et al. (20). Briefly, BT20 cells which had been treated as required were lysed and scraped into 0.5 ml of BOS buffer (50 mM Tris-HCl [pH 7.4], 200 mM NaCl, 1% NP-40, 10% glycerol, 10 mM NaF, 2.5 mM MgCl2, 1 mM EDTA) and then centrifuged at 21,000 x g and 4°C for 30 min. Glutathione S-transferase (GST) fused to the Raf Ras binding domain (GST-RBD), precoupled to glutathione-agarose beads in BOS buffer, was added, and the lysates were incubated at 4°C for 1 h. Beads were collected by centrifugation and washed three times with BOS buffer, and then loading buffer was added. Ras was detected with the monoclonal anti-Ras antibody, followed by a horseradish peroxidase (HRP)-coupled anti-mouse antibody.
Immunoblotting.
Immunoblotting was performed as described previously (40). For the detection of EGFR, pTyr, phospho-ERK, phospho-Akt, phospho-PLC-1, and Raf in total lysates of MDCK and BT20 cells, aliquots containing 20 µg of protein from each cell lysate were used. For the detection of EGFR, SHC, Grb2, PLC-1, and the p85 subunit of PI3K in the anti-EGFR immunoprecipitates, 1/10 of the immunoprecipitate from each lysate was used. To examine EGFR in each subcellular fraction of BT20 and MDCK cells, aliquots containing 5 µg of protein from each fraction were used. The 5 µg of protein represents one-sixth of the total yield for both the PM and EN fractions. Protein samples were separated by electrophoresis through sodium dodecyl sulfate-10% polyacrylamide-containing gels and electrophoretically transferred onto nitrocellulose filter paper. Filters were then probed with the respective primary antibody. The primary antibodies were detected with a polyclonal goat anti-rabbit IgG coupled to HRP or a polyclonal goat anti-mouse IgG coupled to HRP followed by enhanced chemiluminescence development (Pierce Chemical, Rockford, Ill.) and light detection with Fuji (Tokyo, Japan) Super RX film. Quantification of the results was achieved by using a FluorChem digital imaging system (Alpha Innotech Corporation).
TUNEL assay. BT20 and MDCK cells (10,000 per coverslip) were serum starved for 24 (for BT20 cells) or 72 h (for MDCK cells) to initiate a significant level of apoptosis. Some of the serum-starved cells were treated with AG-1478 for 15 min and then with EGF (20 ng/ml) and monensin for 30 min followed by a washing with PBS and incubation with serum-free medium for 12 h. Alternatively, some cells were treated with AG-1478 and EGF (20 ng/ml) for 30 min followed by a 1-min washing with acidic stripping buffer. Cells were then incubated with serum-free medium for 12 h. For controls, some of the serum-starved cells were stimulated with EGF for 30 min, followed by incubation with serum-free medium for 12 h. Apoptosis was assayed by a terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay using an apoptosis detection system kit (Promega) according to the manufacturer's instructions. The percentage of apoptotic cells was calculated as the number of apoptotic nuclei/total nuclei analyzed x 100. For each experimental treatment, a minimum of 250 cells were counted.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
To determine whether endosome-associated nonphosphorylated EGFR could be activated, BT20 cells were washed with medium. The endosome-associated EGFR was significantly activated 30 min following the wash (Fig. 1A to C). The activated EGFR remained colocalized with TR-EGF (Fig. 1C). The fact that similar results were obtained with MDCK cells by immunofluorescence (Fig. 1D) suggests that our observation is not limited to BT20 cells.
These observations were further confirmed by subcellular-fractionation experiments (Fig. 2). It is well established that EGFR is localized at the plasma membrane and not phosphorylated without EGF stimulation and is primarily phosphorylated and localized in endosomes following EGF stimulation for 30 min. Thus EGFR itself could be used as a marker for the plasma membrane and endosomes. Indeed, our results showed that for both BT20 and MDCK cells EGFR was primarily in the PM fraction and was not phosphorylated without EGF stimulation, while EGFR was primarily in the EN fraction and was phosphorylated following standard EGF stimulation (Fig. 2A and Table 1). Additionally, EEA1, a marker for endosomes, is highly enriched in our EN fractions. Treatment with AG-1478, monensin, and EGF resulted in the internalization of nonphosphorylated EGFR into endosomes, and the endosome-associated EGFR was phosphorylated following washing and incubation in medium (Fig. 2A and Table 1). Washing away of AG-1478 and monensin did not result in an increase of plasma membrane-associated EGFR (Fig. 2A and Table 1), which suggests that there is no detectable recycling of EGFR from the endosome to the plasma membrane following the removal of monensin. More importantly, no phosphorylated EGFR was detected at the plasma membrane (Fig. 2A and Table 1). A time course of immunofluorescence further showed that there was no detectable EGFR and EGFR phosphorylation at the plasma membrane following the removal of monensin, which further indicates that there is no detectable recycling of EGFR from the endosome to the plasma membrane following the removal of monensin (Fig. 2B). Together, these results suggest that we have established a system to specifically activate EGFR in endosomes without any detectable EGFR activation at the plasma membrane.
|
|
|
|
subunit of PI3K, and PLC-1, were recruited to the plasma membrane by the interaction between EGFR pTyr sites and the signaling proteins (32, 44). Many of these proteins, including Grb2, SHC, and GAP, were then cointernalized with activated EGFR and remained associated with the EGFR in endosomes (10, 14, 17, 25, 40). However, it is unclear whether the direct activation of endosome-associated EGFR is able to directly recruit these signaling proteins into endosomes or whether the interaction between EGFR and these signaling proteins has to be initiated at the plasma membrane. To answer this question, BT20 and MDCK cells were treated with AG-1478 and EGF with or without monensin as described above. The cells were then lysed and immunoprecipitated with an anti-EGFR antibody. Immunoblotting the immunoprecipitates revealed the association of EGFR with various signaling proteins following the activation of endosome-associated EGFR (Fig. 5). The signaling proteins that are coimmunoprecipitated with EGFR include SHC, Grb2, and the p85 subunit of PI3K. Our results indicate that direct activation of endosome-associated EGFR is sufficient to recruit some signaling proteins into endosomes.
|
|
However, activation of endosome-associated EGFR only slightly activated PLC-1. While we did not detect phosphorylation of PLC-1 in the total lysates following the activation of endosome-associated EGFR (Fig. 6D), we detected phosphorylation of PLC-1 from EGFR immunoprecipitates (Fig. 6D).
Support of cell survival by endosomal signaling of EGFR. We finally determined whether pure endosomal signaling of EGFR is sufficient to produce a biological outcome. We examined the effects of pure endosomal signaling of EGFR on serum withdrawal-induced apoptosis by a TUNEL assay (Fig. 7). For BT20 cells cultured in 10% FBS, only 5% of cells are apoptotic; however, serum withdrawal for 24 h induced 54% apoptosis. For MDCK cells serum withdrawal for 72 h induced 47% apoptosis, compared with 3% apoptosis in 10% FBS (Fig. 7). To determine the effects of activation of endosome-associated EGFR on apoptosis induced by serum withdrawal, BT20 and MDCK cells were stimulated with EGF (20 ng/ml) for 30 min in the presence of AG-1478 with or without monensin to allow the internalization of inactive EGFR into endosomes. After the subsequent activation of endosome-associated EGFR by stripping and/or washing and incubating with serum-free medium for 12 h, the percentage of apoptotic cells was significantly reduced to a level comparable to that following standard EGF (20 ng/ml) stimulation for 30 min (Fig. 7). These results demonstrate that pure endosomal signaling of EGFR is sufficient to produce a biological effect. Moreover, when the cells were pretreated with wortmannin (100 nM) to block PI3K activity, the activation of endosome-associated EGFR was unable to suppress apoptosis induced by serum withdrawal (Fig. 7). This indicates that, similar to standard activation of EGFR, activation of endosome-associated EGFR supports cell survival by stimulating the PI3K-Akt pathway.
|
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
As demonstrated in this paper, we have established such a system to specifically activate EGFR in endosomes without initial activation at the plasma membrane (Fig. 1 to 4). Following treatment with AG-1478 to inhibit EGFR kinase activation, addition of EGF resulted in the internalization of inactivated EGF-EGFR complex into endosomes with or without monensin (Fig. 1 to 3). In the presence of monensin more than 90% of EGFR was internalized and remained in endosomes following EGF treatment for 30 min (Fig. 2), while only 70 to 80% of EGFR was in the endosome fractions without monensin, possibly due to the recycling of the inactivate EGF-EGFR complex (Fig. 3). We did not observe any increase of the plasma membrane-associated EGFR following the removal of monensin and AG-1478 by washing, which suggests that washing does not lead to the recycling of EGFR. This is not surprising because washing results in the activation of EGFR and activated EGFR is targeted to the lysosome for degradation instead of being recycled back to the plasma membrane. However, in both cases we did not detect any activation of EGFR at the plasma membrane following the activation of endosome-associated EGFR by stripping surface EGF and/or washing away AG-1478 (Fig. 1 to 3). The total phosphorylation level of EGFR following its specific activation in endosomes is approximately 50% of that following the standard activation of EGFR at the plasma membrane (Fig. 4). Two possible processes may explain the lower phosphorylation level: some EGF may be dissociated from EGFR in endosomes, and AG-1478 may not be completely washed away. Nevertheless, our results demonstrate that we have established a system to specifically activate endosome-associated EGFR without detectable activation of surface EGFR.
In this system EGFR follows the same endocytic pathway as the control: the EGFR first is internalized into Rab5-positive endosomes and eventually traffics to lysosomes for degradation. The only difference is that EGFR is not activated during its internalization from the plasma membrane to endosomes and stops at endosomes until being activated. Thus, this system not only allows the generation of pure or nearly pure endosomal signaling of EGFR but also allows it under a condition very similar to the endosomal signaling of EGFR following its activation at the plasma membrane. The establishment of this system allows us to specifically determine EGFR-mediated signaling from endosomes and to address related questions that cannot be elucidated by previous approaches.
The first question we addressed is whether the activated-endosome-associated EGFR is able to recruit various signaling proteins to endosomes. It has been argued that clathrin-coated pits function as nucleation sites for the organization of signaling complexes on the plasma membrane (30). However, we showed by coimmunoprecipitation that activation of endosome-associated EGFR resulted in the interaction with various signaling proteins including SHC, Grb2, and the p85 subunit of PI3K (Fig. 5). Our results indicate that endosomes could also serve as nucleation sites for the organization of signaling complexes.
The second question we addressed is whether endosomal signaling of EGFR itself is sufficient to stimulate various signaling pathways. Previous studies using an endocytosis inhibition approach suggest that endosomal signaling of EGFR is necessary for EGF-induced ERK activation (1, 29, 36, 39). Here we showed that the endosomal signaling of EGFR itself is sufficient to activate various signaling proteins including Ras, ERK, and Akt (Fig. 6). Interestingly, we also showed that PLC-1 is only weakly phosphorylated by the endosomal signaling of EGFR, which suggests that the endosomal signaling of EGFR is not identical to the standard EGFR signaling.
Finally, we determined the physiological relevance of EGFR-mediated signaling from endosomes. Inhibition of EGFR endocytosis blocks EGF-stimulated ERK activation (36). However, in the few cases where biological end points were measured, inhibition of endocytosis did not result in attenuation of biological effects (6, 39). Very recently, it was reported that retrograde support of neuronal survival does not require the retrograde transport (endocytosis) of nerve growth factor (26). These results argue against the physiological relevance of endosome-originated signals (12). Here we showed that endosomal signaling of EGFR itself stimulated the PI3K-Akt pathway, which suggests a role for endosomal EGFR signaling in antiapoptosis. Indeed, we showed by TUNEL assay that activation of endosome-associated EGFR suppressed apoptosis induced by serum withdrawal (Fig. 7). Moreover, this suppression was blocked by treating the cell with wortmannin. We have also shown that endosomal signaling of EGFR is sufficient to activate Akt and that this activation is abolished by wortmannin. Together, our results indicate that the molecular mechanism by which endosomal signaling of EGFR supports cell survival is through the activation of the PI3K-Akt pathway. This provides the original evidence to show that endosomal signaling is sufficient to produce biological outcome.
If we divide the whole-EGFR signaling into two components, signaling from the plasma membrane and signaling from endosomes, we clearly demonstrate that eliminating the initial signaling from the plasma membrane does not affect the ability of EGFR to activate major signaling pathways and to provide a physiological response. Moreover, following EGF stimulation, activated EGFR only remains at the plasma membrane briefly (5 to 10 min) but remains at the endosome much longer (1 h) (5, 38). This argues for a more important role for endosome signaling.
In summary, we have successfully established a system to allow the specific activation of endosome-associated EGFR without the initial activation at the plasma membrane. By using this system, we determined the roles of endosomal EGFR signaling in cell mitogenesis and antiapoptosis. We provided original evidence demonstrating that the endosome can serve as a nucleation site for the formation of signaling complexes and that endosomal EGFR signaling is sufficient to activate the major signaling pathways leading to cell proliferation and antiapoptosis. We also demonstrate that pure endosomal EGFR signaling is sufficient to suppress apoptosis induced by serum withdrawal. The same approach could be applied to study endosomal signaling of other receptor tyrosine kinases including platelet-derived growth factor receptor and nerve growth factor receptor.
|
ACKNOWLEDGMENTS |
|---|
This work was supported in part by grants from the Canadian Institutes of Health Research (CIHR), the Alberta Heritage Foundation for Medical Research (AHFMR), and the Natural Science and Engineering Council of Canada. Z.W. is a CIHR Scholar and an AHFMR Scholar.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
2. Barbieri, M. A., R. L. Roberts, A. Gumusboga, H. Highfield, C. Alvarez-Dominguez, A. Wells, and P. D. Stahl. 2000. Epidermal growth factor and membrane trafficking. EGF receptor activation of endocytosis requires Rab5a. J. Cell Biol. 151:539-550.
3. Burgering, B. M., and P. J. Coffer. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602.[CrossRef][Medline]
4. Burke, P., K. Schooler, and H. S. Wiley. 2001. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12:1897-1910.
5. Carpenter, G. 1987. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56:881-914.[CrossRef][Medline]
6. Ceresa, B. P., A. W. Kao, S. R. Santeler, and J. E. Pessin. 1998. Inhibition of clathrin-mediated endocytosis selectively attenuates specific insulin receptor signal transduction pathways. Mol. Cell. Biol. 18:3862-3870.
7. Ceresa, B. P., and S. L. Schmid. 2000. Regulation of signal transduction by endocytosis. Curr. Opin. Cell Biol. 12:204-210.[CrossRef][Medline]
8. Chen, W. S., C. S. Lazar, K. A. Lund, J. B. Welsh, C. P. Chang, G. M. Walton, C. J. Der, H. S. Wiley, G. N. Gill, and M. G. Rosenfeld. 1989. Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59:33-43.[CrossRef][Medline]
9. Chen, X., and Z. Wang. 2001. Regulation of intracellular trafficking of the EGF receptor by Rab5 in the absence of phosphatidylinositol 3-kinase activity. EMBO Rep. 2:68-74.[CrossRef][Medline]
10. Clague, M. J., and S. Urbe. 2001. The interface of receptor trafficking and signalling. J. Cell Sci. 114:3075-3081.
11. Cohen, S., and R. A. Fava. 1985. Internalization of functional epidermal growth factor: receptor/kinase complexes in A-431 cells. J. Biol. Chem. 260:12351-12358.
12. Di Fiore, P. P., and P. De Camilli. 2001. Endocytosis and signaling: an inseparable partnership. Cell 106:1-4.[CrossRef][Medline]
13. Di Fiore, P. P., and G. N. Gill. 1999. Endocytosis and mitogenic signaling. Curr. Opin. Cell Biol. 11:483-488.[CrossRef][Medline]
14. Di Guglielmo, G. M., P. C. Baass, W. J. Ou, B. I. Posner, and J. J. Bergeron. 1994. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J. 13:4269-4277.[Medline]
15. Downward, J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10:262-267.[CrossRef][Medline]
16. Felder, S., K. Miller, G. Moehren, A. Ullrich, J. Schlessinger, and C. R. Hopkins. 1990. Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body. Cell 61:623-634.[CrossRef][Medline]
17. Fukazawa, T., S. Miyake, V. Band, and H. Band. 1996. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271:14554-14559.
18. Glenney, J. R., Jr., W. S. Chen, C. S. Lazar, G. M. Walton, L. M. Zokas, M. G. Rosenfeld, and G. N. Gill. 1988. Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies. Cell 52:675-684.[CrossRef][Medline]
19. Haugh, J. M., A. C. Huang, H. S. Wiley, A. Wells, and D. A. Lauffenburger. 1999. Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J. Biol. Chem. 274:34350-34360.
20. Herrmann, C., G. A. Martin, and A. Wittinghofer. 1995. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J. Biol. Chem. 270:2901-2905.
21. Kay, D. G., W. H. Lai, M. Uchihashi, M. N. Khan, B. I. Posner, and J. J. Bergeron. 1986. Epidermal growth factor receptor kinase translocation and activation in vivo. J. Biol. Chem. 261:8473-8480.
22. Kuruvilla, R., H. Ye, and D. D. Ginty. 2000. Spatially and functionally distinct roles of the PI3-K effector pathway during NGF signaling in sympathetic neurons. Neuron 27:499-512.[CrossRef][Medline]
23. Lai, W. H., P. H. Cameron, J. J. Doherty II, B. I. Posner, and J. J. Bergeron. 1989. Ligand-mediated autophosphorylation activity of the epidermal growth factor receptor during internalization. J. Cell Biol. 109:2751-2760.
24. Lanzetti, L., V. Rybin, M. G. Malabarba, S. Christoforidis, G. Scita, M. Zerial, and P. P. Di Fiore. 2000. The Eps8 protein coordinates EGF receptor signalling through Rac and trafficking through Rab5. Nature 408:374-377.[CrossRef][Medline]
25. Levkowitz, G., H. Waterman, E. Zamir, Z. Kam, S. Oved, W. Y. Langdon, L. Beguinot, B. Geiger, and Y. Yarden. 1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:3663-3674.
26. MacInnis, B. L., and R. B. Campenot. 2002. Retrograde support of neuronal survival without retrograde transport of nerve growth factor. Science 295:1536-1539.
27. Marshall, C. J. 1994. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4:82-89.[CrossRef][Medline]
28. Marshall, C. J. 1996. Cell signalling. Raf gets it together. Nature 383:127-128.[CrossRef][Medline]
29. Maudsley, S., K. L. Pierce, A. M. Zamah, W. E. Miller, S. Ahn, Y. Daaka, R. J. Lefkowitz, and L. M. Luttrell. 2000. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J. Biol. Chem. 275:9572-9580.
30. McPherson, P. S., B. K. Kay, and N. K. Hussain. 2001. Signaling on the endocytic pathway. Traffic 2:375-384.[CrossRef][Medline]
31. Miller, W. E., and R. J. Lefkowitz. 2001. Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr. Opin. Cell Biol. 13:139-145.[CrossRef][Medline]
32. Pawson, T. 1995. Protein modules and signalling networks. Nature 373:573-580.[CrossRef][Medline]
33. Pawson, T. 1997. New impressions of Src and Hck. Nature 385:582-585.[Medline]
34. Schlessinger, J. 1986. Allosteric regulation of the epidermal growth factor receptor kinase. J. Cell Biol. 103:2067-2072.
35. Schlessinger, J., and A. Ullrich. 1992. Growth factor signaling by receptor tyrosine kinases. Neuron 9:383-391.[CrossRef][Medline]
36. Shen, Y., L. Xu, and D. A. Foster. 2001. Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell. Biol. 21:595-602.
37. Slepnev, V. I., and P. De Camilli. 2000. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nat. Rev. Neurosci. 1:161-172.[Medline]
38. Sorkin, A., and G. Carpenter. 1993. Interaction of activated EGF receptors with coated pit adaptins. Science 261:612-615.
39. Vieira, A. V., C. Lamaze, and S. L. Schmid. 1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274:2086-2089.
40. Wang, Z., P. S. Tung, and M. F. Moran. 1996. Association of p120 ras GAP with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation. Cell Growth Differ. 7:123-133.[Abstract]
41. Wang, Z., L. Zhang, T. K. Yeung, and X. Chen. 1999. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol. Biol. Cell 10:1621-1636.
42. Waterman, H., I. Alroy, S. Strano, R. Seger, and Y. Yarden. 1999. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J. 18:3348-3358.[CrossRef][Medline]
43. Wiley, H. S., and P. M. Burke. 2001. Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2:12-18.[CrossRef][Medline]
44. Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
